Dr. Sithu Lin, MD

Dr. Lin practices at U.S. Renal Care Modesto Dialysis in Modesto, California.

Dr. Lin's NPI, 1023417649, was assigned on August 19, 2014. Dr. Lin graduated from University Institute of Medicine 1 in 2008. Dr. Lin holds California license A-143411.

Dr. Lin's primary practice is U.S. Renal Care Modesto Dialysis, at 305 East Granger, Modesto, CA 95350 in Stanislaus County. The practice phone is (209) 574-6800.

Dr. Lin's primary practice is U.S. Renal Care Modesto Dialysis in Modesto, California. Dr. Lin is also affiliated with Memorial Medical Center. The medical group on file is Golden Valley Health Centers. Dmand AI also links Dr. Lin to 4 more hospitals, 3 medical groups, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lin practices, 8 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Lin's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Lin is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Lin's licenses on file in 6 states: California, New York, Pennsylvania, Hawaii, Texas and Delaware.

Dmand AI lists chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Lin treats.

CMS data shows 83 Medicare services from Dr. Lin across 3 procedure codes in 2024, for 51 Medicare patients. Medicare paid $7,828 for them.

CMS counts 51 Medicare patients who saw Dr. Lin in 2024. The largest group is 75 to 84, with 21 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 45% are also on Medicaid. Their average risk score is 5.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lin's median patient age at 68, with 49% women.

In 2024, Dr. Lin wrote 801 Medicare Part D claims for 179 patients. 83% of them were for generic drugs. CMS names the drug for 602 of them, across 18 drugs with 11 or more claims each, at $68,652 in total drug cost. In 2023, CMS named 125 claims across 6 drugs.

Dr. Lin accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 9 papers to Dr. Lin, published from 2017 to 2018. 2017 was the busiest year, with 7. The most frequent topics are Adrenergic beta-Antagonists. Dr. Lin has published most often in BMJ Case Rep. Dr. Lin's most frequent co-authors are Thinzar Lin, MD, Deepika Misra, MD and Madhavi Reddy, MD.

CMS Open Payments shows 30 general payments to Dr. Lin from 15 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 96% of the total. Novo Nordisk Inc paid the most, $380.

Dr. Lin graduated from University Institute of Medicine 1 in 2008. Dr. Lin is a member of ACP.

Dr. Lin is in network with 17 carriers, including Aetna, Elevance and Highmark. Medicare plans come from the most carriers, 13. Check the plan with the practice before a visit.